---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284616482.md"
description: "Oruka Therapeutics shares are trading lower after the company priced an upsized $700 million public offering of 9.66 million shares at $72.50 per share."
datetime: "2026-04-29T16:51:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284616482.md)
  - [en](https://longbridge.com/en/news/284616482.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284616482.md)
---

# 

Oruka Therapeutics shares are trading lower after the company priced an upsized $700 million public offering of 9.66 million shares at $72.50 per share.

### Related Stocks

- [ORKA.US](https://longbridge.com/en/quote/ORKA.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Barclays Remains a Buy on Oruka Therapeutics (ORKA)](https://longbridge.com/en/news/286389801.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)